Event-Driven Stocks

NUPATHE INC.

Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕

Signs3 warningdetails ↓

Financials

SEC XBRL · annual
 FY12FY11FY10
Revenue
Operating income−$111.2M−$21.8M−$21.2M
Net income−$6.3M−$3.7M−$24.4M
Total assets$30.6M$30.8M$43.8M
Total liabilities$27.6M$17.9M$9.5M
Equity$3.0M$13.0M$34.3M
EPS (diluted)
Shares out.14.7M14.7M14.5M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2012
Operating margin
Net margin
Return on equity
−208.6%
Return on assets
−20.5%
Return on capital (ROCE)
−405.2%
Liabilities / assets
90.2%
Debt / equity
9.16×
Book value / share
$0.20
Revenue growth (YoY)
Net income growth (YoY)

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2012
Accruals / assets
302.8%high accruals
Piotroski F-Score
2/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
25
/ 100
Profitability 0Growth n/aCatalyst 33Earnings quality 0Financial strength 67

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

3 warning0 good
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • High accruals — earnings-quality risk

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Insider transactions

SEC Form 4 · most recent
1 acquisitions11 disposalsnet 5.2M shares · last 12
InsiderDateTypeSharesPrice
Safeguard Scientifics IncDirectorFeb 21, 2014U5.2M$3.65
Roche Robert P JrDirectorFeb 21, 2014U10,000$6.80
Yetter Wayne P.DirectorFeb 21, 2014D13,500$6.80
Mclaughlin Gerald W.Officer — SVP, Chief Commercial OfficerFeb 21, 2014U11,771$6.80
Federici William JDirectorFeb 21, 2014D13,500$6.80
Goldan Keith A.Officer — CFO and SVPFeb 21, 2014U18,875$6.80
Cola Michael FDirectorFeb 21, 2014D13,500$6.80
Datin James ADirectorFeb 21, 2014U20,620$6.80
Sebree Terri BOfficer — PresidentFeb 21, 2014U176,699$6.80
Anido ArmandoOfficer — Chief Executive OfficerFeb 21, 2014D1.3M$6.80
Marino Michael F IiiOfficer — SVP and General CounselFeb 21, 2014U10,992$6.80
Glaxosmithkline PlcFeb 6, 2014Conversion1.5M$2.00

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.